Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06978725 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
A Phase 2 study of Cutaneous Sarcoidosis, sponsored by Priovant Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT06978725 is a Phase 2 study of Cutaneous Sarcoidosis that is actively recruiting participants, run by Priovant Therapeutics. The registered enrollment target is 28 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT06978725, a Phase 2 study of Cutaneous Sarcoidosis, is actively recruiting participants, sponsored by Priovant Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Conditions Studied
Interventions
- DRUG Oral Brepocitinib
- DRUG Oral Placebo
Study Locations (4)
California
- Clinical Trial Site - San Francisco
North Carolina
- Clinical Trial Site - Durham
Pennsylvania
- Clinical Trial Site - Philadelphia
Wisconsin
- Clinical Trial Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06978725
The ClinicalTrials.gov registry entry for NCT06978725 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Priovant Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Sarcoidosis appearing as the primary indexed condition, and to 2 interventions - of which Oral Brepocitinib is the first listed.
NCT06978725 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06978725 about?
NCT06978725 is a clinical study titled "A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)". This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
What is the current status of trial NCT06978725?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-04-09. Estimated completion is 2026-12.
What conditions does trial NCT06978725 study?
This clinical trial studies the following conditions: Cutaneous Sarcoidosis.
What interventions are being tested in trial NCT06978725?
The interventions under investigation include: Oral Brepocitinib (DRUG), Oral Placebo (DRUG).
Who is sponsoring clinical trial NCT06978725?
This trial is sponsored by Priovant Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06978725 being conducted?
This trial has 4 study locations across California, North Carolina, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.